{"id":"arginine-lysine","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Arginine is a semi-essential amino acid involved in nitric oxide production, immune cell proliferation, and wound healing. Lysine is an essential amino acid that plays roles in collagen formation and immune response. Together, they may support immune function, though the specific mechanism for any marketed formulation by Advanced Accelerator Applications is not well-established in standard pharmaceutical literature.","oneSentence":"Arginine and lysine are amino acids that support immune function and may enhance natural killer cell activity and protein synthesis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:17:55.896Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune support (specific indication unclear)"}]},"trialDetails":[{"nctId":"NCT06991738","phase":"PHASE1, PHASE2","title":"177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2026-04-01","conditions":"Thyroid Cancer","enrollment":18},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT05660083","phase":"PHASE2","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-01-12","conditions":"HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma","enrollment":36},{"nctId":"NCT04711135","phase":"PHASE2","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2022-08-31","conditions":"Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":11},{"nctId":"NCT07150806","phase":"PHASE1, PHASE2","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","status":"RECRUITING","sponsor":"Joshua Palmer","startDate":"2025-11-12","conditions":"Recurrent Meningioma","enrollment":30},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":"Somatostatin Receptor Positive, NETs, Lymphoma","enrollment":20},{"nctId":"NCT06148636","phase":"EARLY_PHASE1","title":"A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bushnell","startDate":"2023-11-10","conditions":"Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1","enrollment":24},{"nctId":"NCT05400733","phase":"NA","title":"Prandial Metabolic Phenotype in Adults","status":"RECRUITING","sponsor":"Texas A&M University","startDate":"2022-06-24","conditions":"Protein Metabolism","enrollment":50},{"nctId":"NCT04919226","phase":"PHASE3","title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":259},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT04524442","phase":"PHASE4","title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2021-01-25","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":42},{"nctId":"NCT02499926","phase":"NA","title":"Lysine Oxidation in Response to Arginine Supplementation","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2015-07","conditions":"Physiologically Healthy Adult Male Participants","enrollment":5},{"nctId":"NCT05475210","phase":"PHASE1","title":"177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Molecular Targeting Technologies, Inc.","startDate":"2022-06-18","conditions":"Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT05706714","phase":"","title":"Th1, Th2, Th17 Phenotype in Urea Cycle Disorders","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2021-04-06","conditions":"Urea Cycle Disorder, Lysinuric Protein Intolerance","enrollment":65},{"nctId":"NCT02592707","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs","status":"TERMINATED","sponsor":"Ipsen","startDate":"2017-03-06","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT05785663","phase":"","title":"AminoMedixTM for Kidney Protection During Radionuclide Therapy","status":"COMPLETED","sponsor":"Excel Diagnostics and Nuclear Oncology Center","startDate":"2014-08-08","conditions":"Radiation Nephropathy","enrollment":28},{"nctId":"NCT03273712","phase":"PHASE2","title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2017-09-29","conditions":"Neuroendocrine Tumors, Meningioma, Neuroblastoma","enrollment":39},{"nctId":"NCT03478358","phase":"PHASE1","title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-04-30","conditions":"Neuroendocrine Tumors","enrollment":60},{"nctId":"NCT04664712","phase":"NA","title":"Efficacy of Focused Shock Waves Combined With Adjuvant Therapy With Tendon Supplement","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","startDate":"2019-09-11","conditions":"Fasciitis, Plantar","enrollment":44},{"nctId":"NCT04510181","phase":"NA","title":"Effect of an Amino-Acid-Based Blend on Human Growth Hormone (hGH) and Fibromyalgia (FM) Symptoms","status":"UNKNOWN","sponsor":"Pekarovics, Susan, MD","startDate":"2020-08-01","conditions":"Fibromyalgia","enrollment":100},{"nctId":"NCT03306498","phase":"","title":"Plasma Free Amino Acids in Patients With Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-12-15","conditions":"Hepatic Encephalopathy","enrollment":100},{"nctId":"NCT03013387","phase":"PHASE2","title":"Dosimetry Guided PRRT With 90Y-DOTATOC","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2017-01","conditions":"Neuroendrocrine Tumors, Meningioma, Neuroblastoma","enrollment":""},{"nctId":"NCT00228943","phase":"NA","title":"The Role of Serotonin in Hot Flashes After Breast Cancer","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2005-07","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT00175084","phase":"NA","title":"Effect of Dietary Amino Acid Profile on Lipoprotein Metabolism, Vascular Reactivity and Inflammatory Markers","status":"COMPLETED","sponsor":"Tufts University","startDate":"2004-10","conditions":"Hyperlipidemias, Metabolic Syndrome X, Cardiovascular Diseases","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":40,"reaction":"PLATELET COUNT DECREASED"},{"count":37,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":28,"reaction":"ANAEMIA"},{"count":20,"reaction":"LYMPHOCYTE COUNT DECREASED"},{"count":19,"reaction":"INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION"},{"count":16,"reaction":"WHITE BLOOD CELL COUNT DECREASED"},{"count":14,"reaction":"DECREASED APPETITE"},{"count":14,"reaction":"NAUSEA"},{"count":13,"reaction":"DIARRHOEA"},{"count":12,"reaction":"MYELOSUPPRESSION"}],"_approvalHistory":[],"publicationCount":670,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LysaKare"],"phase":"marketed","status":"active","brandName":"arginine/lysine","genericName":"arginine/lysine","companyName":"Advanced Accelerator Applications","companyId":"advanced-accelerator-applications","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arginine and lysine are amino acids that support immune function and may enhance natural killer cell activity and protein synthesis. Used for Immune support (specific indication unclear).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}